UNCY

Phase 2 single-arm, non-randomized, non-placebo-controlled study enrolling 106 patients with chronic kidney disease requiring dialysis. Participants received oxylanthanum carbonate and were monitored for safety, tolerability, and pharmacokinetics including lanthanum Cmax, AUC, Tmax, and elimination half-life.

primary endpoint:Incidence of treatment-related adverse events leading to study drug discontinuation during the Maintenance Period (4 weeks)

Nanoparticle technology enables higher phosphate binding potency resulting in smaller pill size, fewer pills, and improved palatability (swallowed whole vs chewed) compared to existing phosphate binders, potentially improving patient adherence.

• Vague 'proprietary nanoparticle technology' claim without specific technical details or peer-reviewed validation
• 'Next-generation' and 'high potency' assertions based only on single rat study comparing different doses to an existing drug, not head-to-head clinical data
• No comparative clinical data presented demonstrating superiority in phosphate lowering vs existing binders
• Reliance on patient compliance improvement claims (smaller pills, palatability) as primary differentiation without clinical adherence data
• UNI-494 described as 'first-in-class' for AKI but no clinical data provided in filing
• Management team 'advantage' claim is vague and unsubstantiated

• Manufacturing compliance risk - FDA issued CRL due to cGMP deficiencies at third-party CDMO
• Regulatory risk - NDA required resubmission after CRL
• Competition from six existing approved phosphate binders
• Patient adherence challenges inherent to phosphate binder therapy
• Risk of insufficient differentiation to displace incumbent therapies

• June 29, 2026PDUFA target action date for OLC NDA resubmission